The Rumored ~$40 Billion Merck-Seagen Combination Will Have To Wait A Tick...

Apparently. . . the proverbial people at the WSJ, "familiar with the matter" say both sides have various things to announce at their respective next earnings calls -- which will be on the same day for both Merck and Seagen, on July 28. We await word on how those developments might affect timing, and perhaps even pricing.

Also complicating the matter is that while Seagen recently won an infringement jury trial in rural Texas, against Daiichi-Sankyo for one of its key patents (the so-called '39 patent), Sankyo has been granted a review in DC, at the USPTO, of whether the '039 patent should ever have issued to Seagen in the first place. We expect this will all resolve itself in favor of Seagen, but when. . . is the $40 billion question. So, we will keep you posted here -- in the power alley.

Onward, grinning. . . and catching up on last week's Merck news, now.

नमस्ते